MORRISVILLE, NC, October 24, 2024 – Premier Research, a leading global clinical research, product development, and consulting company, in partnership with Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, is pleased to celebrate the dosing of the first patient in the INVISE (Injectable Vectors for In Situ Engineering) clinical trial. This pioneering phase I study, evaluating the safety of a single INT2104 infusion in adults with refractory/relapsing B cell malignancies, marks the first in-human clinical trial of an in vivo Chimeric Antigen Receptor (CAR) gene therapy. Premier Research is managing this clinical trial in collaboration with Interius BioTherapeutics.
“We are incredibly proud to have reached this milestone with Interius,” said Premier Research Chief Executive Officer, John Ratliff. “Dosing the first patient in this first-of-its-kind study underscores the dedication of our research team and the invaluable work and support of our partners at Interius. We are encouraged by the possibility to deliver a transformative new therapy to patients with refractory/relapsing B cell malignancies, as well as the potential for this study to spur future innovation in cancer care.”
“In vivo CAR therapies have the potential to be an off-the-shelf solution, ready for use at the time of patient referral,” said Premier Research Senior Vice President, Oncology, Elaina Haeuber. “Working together with Interius, we have the opportunity to offer an alternative treatment option that supports greater scalability and accessibility, which could be a game changer for patients in need.”
About Premier Research
Premier Research, a global clinical research, product development, and consulting company, is dedicated to helping innovators transform life-changing ideas and breakthrough science into new medical treatments. We offer strategic solutions across the entire development lifecycle, from pre-clinical through commercialization, specializing in smart study design and full-service clinical trial management. Leveraging technology and therapeutic expertise, we deliver clean, conclusive data with a focus on reducing development timelines, securing access to the right patients, and effectively navigating global regulations to ensure submission-ready results. As an organization that puts patients first, we pride ourselves on helping customers answer the unmet needs of patients across a broad range of medical conditions. Visit premier-research.com.